Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare updates oral Rx demonstration

Executive Summary

Pfizer's Somavert (pegvisomant) for treatment of acromegaly and Baxter's Mesnex (mesna) for reduction of ifosfamide-induced hemorrhagic cystitis will be reimbursed by the Medicare Part B replacement drug demonstration under an 1updated list of covered drugs. The original list of drugs included thirteen for oncology and fourteen for other indications (2"The Pink Sheet" June 28, 2004, p. 23)...

You may also be interested in...

Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen, Thalidomide

Tamoxifen and thalidomide will be covered under the Medicare Part B oral drug replacement demonstration project, the Centers for Medicare & Medicaid Services said in announcing the start of the project June 24

Trump Pushes Back On OIG Report That Hospitals Want Feds To Better Police Resources, Relax Regs

When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.

Execs On The Move: Promotions Are In The Spotlight At Terumo And MiMedx Group

Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts